This trial is unknown!
Search for a recruiting clinical trial for your condition
You can access this
clinical trial
if you have
Diastolic Heart Failure
and you are
over 18
years old
Phase
3
This is a trial in the final phase before the treatment is released on the market.
Show me locations

The purpose

The investigators hypothesized that udenafil, a newly developed phosphodiesterase type 5 inhibitor, would improve symptom, exercise capacity and hemodynamic status in patients with heart failure with preserved ejection fraction (HFpEF).

Provided treatments

  • Drug: Placebo
  • Drug: Udenafil (Zydena)
Tris trial is registered with FDA with number: NCT01599117. The sponsor of the trial is Seoul National University Hospital and it is looking for 52 volunteers for the current phase.
Official trial title:
Udenafil Therapy to Improve Symptomatology, Exercise Tolerance and Hemodynamics in Patients With Heart Failure With Preserved Ejection Fraction: Phase III, Randomized, Double-blind, Placebo-controlled Trial [ULTIMATE-HFpEF Trial]